Gayle Ross
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gayle Ross has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
Vanessa Morgan
Department of Dermatology Royal Melbourne Hospital Parkville Victoria Australia
5 shared publications- Jessica McClatchy
Dermatology Department The Royal Melbourne Hospital Melbourne Victoria Australia
3 shared publications - Nadine Abu‐Ghazaleh
Department of Dermatology Royal Melbourne Hospital Parkville Victoria Australia
3 shared publications - Anand Ramakrishnan
Department of Plastic and Reconstructive Surgery The Royal Melbourne Hospital Parkville Australia
2 shared publications Daniel P. O'BRien
2 shared publications- Euzebiusz Jamrozik
Ethox and Pandemic Sciences Institute, University of Oxford
2 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Wiley in The Journal of Dermatology
Study Design and Baseline Characteristics of APOLLO : A Phase 3 Study of Bitopertin in Erythropoietic Protoporphyria and X‐Linked Protoporphyria
Erythropoietic protoporphyria (EPP) and X‐linked protoporphyria (XLP) are characterized by protoporphyrin IX (PPIX) accumulation, causing debilitating cutaneous phototoxic reactions and, in some cases, protoporphyric hepatopathy. Glycine transporter 1 (GlyT1) supplies extracellular glycine for erythroid heme biosynthesis. Bitopertin is an investigational oral GlyT1 inhibitor shown to significantly reduce PPIX and improve light tolerance and quality of life in patients with EPP or XLP. APOLLO is a global randomized, double‐blind, placebo‐controlled Phase 3 study designed to confirm the safety, tolerability, and efficacy of bitopertin in adults and adolescents with EPP or XLP. Eligible participants were ≥ 12 years of age with diagnosis by biochemical and/or genetic testing and randomized 1:1 to receive once‐daily oral bitopertin 60 mg or placebo over 24 weeks. Co‐primary endpoints are percent change in whole blood metal‐free PPIX and average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 and 18:00 after 24 weeks. The general design and participants' baseline characteristics are described herein. Between April 2025 and March 2026, 199 patients were screened at 28 study sites in the United States, Canada, Europe, United Kingdom, and Australia; 183 participants were randomized. Mean (SD) age was 37.1 ± 17.1 years; 59% were female and 91% were White. Most participants (93%) had EPP, whereas 7% had XLP. Overall, 60% had not received prior treatment for EPP; 28% and 18% previously received afamelanotide or dersimelagon, respectively. Adolescents (12 to < 18 years) represented 19% of enrolled participants, and most adolescents (85%) had not previously received afamelanotide or dersimelagon. APOLLO is designed to evaluate bitopertin as a potential disease‐modifying therapy for EPP and XLP. Baseline demographic and disease characteristics were consistent with prior EPP/XLP and generally support the relevance of the study's safety and efficacy findings to the broader EPP/XLP population.
- 15 November 2026
- Published by Wiley in The Journal of Dermatology
Open AccessStudy Design and Baseline Characteristics of APOLLO : A Phase 3 Study of Bitopertin in Erythropoietic Protoporphyria and X‐Linked Protoporphyria
Erythropoietic protoporphyria (EPP) and X‐linked protoporphyria (XLP) are characterized by protoporphyrin IX (PPIX) accumulation, causing debilitating cutaneous phototoxic reactions and, in some cases, protoporphyric hepatopathy. Glycine transporter 1 (GlyT1) supplies extracellular glycine for erythroid heme biosynthesis. Bitopertin is an investigational oral GlyT1 inhibitor shown to significantly reduce PPIX and improve light tolerance and quality of life in patients with EPP or XLP. APOLLO is a global randomized, double‐blind, placebo‐controlled Phase 3 study designed to confirm the safety, tolerability, and efficacy of bitopertin in adults and adolescents with EPP or XLP. Eligible participants were ≥ 12 years of age with diagnosis by biochemical and/or genetic testing and randomized 1:1 to receive once‐daily oral bitopertin 60 mg or placebo over 24 weeks. Co‐primary endpoints are percent change in whole blood metal‐free PPIX and average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 and 18:00 after 24 weeks. The general design and participants' baseline characteristics are described herein. Between April 2025 and March 2026, 199 patients were screened at 28 study sites in the United States, Canada, Europe, United Kingdom, and Australia; 183 participants were randomized. Mean (SD) age was 37.1 ± 17.1 years; 59% were female and 91% were White. Most participants (93%) had EPP, whereas 7% had XLP. Overall, 60% had not received prior treatment for EPP; 28% and 18% previously received afamelanotide or dersimelagon, respectively. Adolescents (12 to < 18 years) represented 19% of enrolled participants, and most adolescents (85%) had not previously received afamelanotide or dersimelagon. APOLLO is designed to evaluate bitopertin as a potential disease‐modifying therapy for EPP and XLP. Baseline demographic and disease characteristics were consistent with prior EPP/XLP and generally support the relevance of the study's safety and efficacy findings to the broader EPP/XLP population.
- 9 September 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Why do Australian dermatologists screen for Strongyloides stercoralis before dupilumab?
We examined why the majority (86%) of Australian dermatologists surveyed screen universally for Strongyloides prior to commencing dupilumab, despite the low seroprevalence of Strongyloides infection (1.4%) and absence of cases of hyperinfection across 887 person-years of dupilumab exposure in our cohort. This work includes an audit of 325 patients prescribed dupilumab for atopic dermatitis and a national survey of Australian dermatologists to determine screening practices. We found that universal screening occurs because of concern regarding the mechanism of action of dupilumab conferring high risk of disseminated strongyloidiasis, peer practice and lack of screening guidelines. The strongest motivator to change this practice would be the introduction of screening guidelines.
- 9 September 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Why do Australian dermatologists screen for Strongyloides stercoralis before dupilumab?
We examined why the majority (86%) of Australian dermatologists surveyed screen universally for Strongyloides prior to commencing dupilumab, despite the low seroprevalence of Strongyloides infection (1.4%) and absence of cases of hyperinfection across 887 person-years of dupilumab exposure in our cohort. This work includes an audit of 325 patients prescribed dupilumab for atopic dermatitis and a national survey of Australian dermatologists to determine screening practices. We found that universal screening occurs because of concern regarding the mechanism of action of dupilumab conferring high risk of disseminated strongyloidiasis, peer practice and lack of screening guidelines. The strongest motivator to change this practice would be the introduction of screening guidelines.
- 20 August 2026
- Published by Wiley in Australasian Journal of Dermatology
Patient Perspectives on Dupilumab Therapy for Atopic Dermatitis: Experiences, Expectations and Treatment Impact
Background: Atopic dermatitis ( AD ) is a chronic inflammatory skin disease characterised by epidermal barrier dysfunction and type 2 immune dysregulation. Dupilumab was the first biologic approved for severe AD and has transformed management of moderate‐to‐severe disease. Although clinical trials and international real‐world studies have demonstrated sustained efficacy and acceptable tolerability, Australian data describing patient‐reported experience with dupilumab remain limited. Methods: We conducted a cross‐sectional survey study of adults receiving dupilumab for moderate‐to‐severe AD at the Royal Melbourne Hospital dermatology clinic. Over a two‐month period, QR codes linked to an anonymous electronic questionnaire displayed in waiting areas and consultation rooms. Survey data were collected and managed using REDCap (Research Electronic Data Capture). The questionnaire examined treatment administration, perceived effectiveness, symptom change, treatment satisfaction, ocular and non‐ocular adverse effects and concomitant therapy use. Results: During the recruitment period, 68 patients receiving dupilumab attended clinic and were eligible to participate; 48 completed the survey, corresponding to a response rate of 70.6%. Most respondents reported marked clinical benefit, with 66.7% reporting significant improvement in eczema control and 22.9% reporting complete resolution. Overall satisfaction was high, with 83.3% reporting being satisfied or very satisfied with treatment. Dupilumab was perceived as more effective than previous therapies by 83.3% of patients. Ocular symptoms were common amongst the cohort. Conclusions: In this tertiary australian cohort, patients treated with dupilumab reported high satisfaction and Substantial improvement in disease control and quality of life. These findings support the real‐world effectiveness of dupilumab and highlight the importance of proactive recognition and management of ocular adverse effects.
- 20 August 2026
- Published by Wiley in Australasian Journal of Dermatology
Patient Perspectives on Dupilumab Therapy for Atopic Dermatitis: Experiences, Expectations and Treatment Impact
Background: Atopic dermatitis ( AD ) is a chronic inflammatory skin disease characterised by epidermal barrier dysfunction and type 2 immune dysregulation. Dupilumab was the first biologic approved for severe AD and has transformed management of moderate‐to‐severe disease. Although clinical trials and international real‐world studies have demonstrated sustained efficacy and acceptable tolerability, Australian data describing patient‐reported experience with dupilumab remain limited. Methods: We conducted a cross‐sectional survey study of adults receiving dupilumab for moderate‐to‐severe AD at the Royal Melbourne Hospital dermatology clinic. Over a two‐month period, QR codes linked to an anonymous electronic questionnaire displayed in waiting areas and consultation rooms. Survey data were collected and managed using REDCap (Research Electronic Data Capture). The questionnaire examined treatment administration, perceived effectiveness, symptom change, treatment satisfaction, ocular and non‐ocular adverse effects and concomitant therapy use. Results: During the recruitment period, 68 patients receiving dupilumab attended clinic and were eligible to participate; 48 completed the survey, corresponding to a response rate of 70.6%. Most respondents reported marked clinical benefit, with 66.7% reporting significant improvement in eczema control and 22.9% reporting complete resolution. Overall satisfaction was high, with 83.3% reporting being satisfied or very satisfied with treatment. Dupilumab was perceived as more effective than previous therapies by 83.3% of patients. Ocular symptoms were common amongst the cohort. Conclusions: In this tertiary australian cohort, patients treated with dupilumab reported high satisfaction and Substantial improvement in disease control and quality of life. These findings support the real‐world effectiveness of dupilumab and highlight the importance of proactive recognition and management of ocular adverse effects.
- Open Access
- 11 July 2026
- Published by Wiley in Internal Medicine Journal
- Vol. 56 (10) , 1748-1753
Tolerability of hormonal treatments in acute hepatic porphyria patients
Background: Acute hepatic porphyria (AHP) flares have been associated with female hormones and the use of hormonal treatments. Women with AHP are traditionally advised to avoid exogenous oestrogen and progesterone, limiting options for contraception and management of menorrhagia, dysmenorrhoea and menopausal symptoms. Evidence on specific hormonal therapies is limited; a 2003 study found that 25% of women with acute intermittent porphyria (AIP) experienced attacks with contraceptives containing progesterone, oestrogen or both. Aim: To update the current understanding of the tolerability of hormonal treatments in women with AHP. Methods: An anonymous questionnaire was distributed to women with AHP (acute intermittent porphyria, hereditary coproporphyria and variegate porphyria) via hospital records and a national patient support group, capturing prior hormonal therapy use and associated flares. Results: Thirty responses were analysed; 23 participants had used hormonal therapies. Flares were most frequent in hereditary coproporphyria (66%) and less common in variegate porphyria and acute intermittent porphyria (~20%). No flares were reported with hormone replacement therapy, the progesterone‐only pill or progesterone implants. Flares occurred with combined oral contraceptives (46.6%) and progesterone‐containing intrauterine devices (28.5%), particularly drospirenone‐containing pills. Levonorgestrel‐based therapies, including the Mirena IUD, were better tolerated and often improved symptoms. Conclusions: Although limited by sample size and retrospective design, this study provides clinically useful data on the tolerability of specific hormonal therapies in women with AHP, supporting personalised prescribing and patient counselling for contraception and symptom management.
- 11 July 2026
- Published by Wiley in Internal Medicine Journal
- Vol. 56 (10) , 1748-1753
Open AccessTolerability of hormonal treatments in acute hepatic porphyria patients
Background: Acute hepatic porphyria (AHP) flares have been associated with female hormones and the use of hormonal treatments. Women with AHP are traditionally advised to avoid exogenous oestrogen and progesterone, limiting options for contraception and management of menorrhagia, dysmenorrhoea and menopausal symptoms. Evidence on specific hormonal therapies is limited; a 2003 study found that 25% of women with acute intermittent porphyria (AIP) experienced attacks with contraceptives containing progesterone, oestrogen or both. Aim: To update the current understanding of the tolerability of hormonal treatments in women with AHP. Methods: An anonymous questionnaire was distributed to women with AHP (acute intermittent porphyria, hereditary coproporphyria and variegate porphyria) via hospital records and a national patient support group, capturing prior hormonal therapy use and associated flares. Results: Thirty responses were analysed; 23 participants had used hormonal therapies. Flares were most frequent in hereditary coproporphyria (66%) and less common in variegate porphyria and acute intermittent porphyria (~20%). No flares were reported with hormone replacement therapy, the progesterone‐only pill or progesterone implants. Flares occurred with combined oral contraceptives (46.6%) and progesterone‐containing intrauterine devices (28.5%), particularly drospirenone‐containing pills. Levonorgestrel‐based therapies, including the Mirena IUD, were better tolerated and often improved symptoms. Conclusions: Although limited by sample size and retrospective design, this study provides clinically useful data on the tolerability of specific hormonal therapies in women with AHP, supporting personalised prescribing and patient counselling for contraception and symptom management.
- 21 June 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (5)
A Retrospective Cohort Study of Extended Dupilumab Dosing in Atopic Dermatitis: Assessing the Impact on Disease Severity and Understanding Characteristics Linked to Successful Dose Extension
Dupilumab is effective for moderate‐to‐severe atopic dermatitis, but optimal long‐term dosing is unclear. In this single‐centre retrospective study, 49 patients underwent dose extension to 300 mg Q3W or 300 mg Q4W, with EASI scores remaining low and stable over 18 months. Patients extending for good disease control had higher EASI90 rates. The impact of age, disease severity and therapy duration remains uncertain.
- 21 June 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (5)
A Retrospective Cohort Study of Extended Dupilumab Dosing in Atopic Dermatitis: Assessing the Impact on Disease Severity and Understanding Characteristics Linked to Successful Dose Extension
Dupilumab is effective for moderate‐to‐severe atopic dermatitis, but optimal long‐term dosing is unclear. In this single‐centre retrospective study, 49 patients underwent dose extension to 300 mg Q3W or 300 mg Q4W, with EASI scores remaining low and stable over 18 months. Patients extending for good disease control had higher EASI90 rates. The impact of age, disease severity and therapy duration remains uncertain.
- 14 April 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (8) , 1600-1610
Applications of Machine Learning, Natural Language Processing, and Generative Artificial Intelligence in Dermatology Education and Research: A Scoping Review
Artificial intelligence (AI) is being increasingly used in dermatology education and research as digital health data expands and large language models (LLMs) advance. This scoping review synthesized current applications, benefits, and limitations of AI in these domains. The review followed PRISMA‐ScR methodology, including 102 studies published between 2010 and 2025, with 28 studies examining educational applications and 74 examining research applications. Educational applications included the use of LLMs for examination preparation, question and case generation, and image‐based learning through generative and adaptive imaging tools. Research applications included machine learning and natural language processing for large‐scale data analysis, pharmacovigilance, social media and clinical text mining, predictive modeling, biomarker and gene‐signature discovery, and the use of LLMs to support literature synthesis, manuscript writing, and research workflow tasks. Across education and research, key limitations related to accuracy, bias, transparency, and ethical governance. These issues highlight the need for ongoing human oversight, the use of dermatology‐specific training datasets, and structured implementation frameworks. Despite these considerations, AI has substantial potential to enhance dermatology learning and improve dermatologic research efficiency. Future work should focus on evaluating real‐world performance, model reliability, and the effectiveness of human‐AI collaboration in dermatology practice and training. image
- 14 April 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (8) , 1600-1610
Applications of Machine Learning, Natural Language Processing, and Generative Artificial Intelligence in Dermatology Education and Research: A Scoping Review
Artificial intelligence (AI) is being increasingly used in dermatology education and research as digital health data expands and large language models (LLMs) advance. This scoping review synthesized current applications, benefits, and limitations of AI in these domains. The review followed PRISMA‐ScR methodology, including 102 studies published between 2010 and 2025, with 28 studies examining educational applications and 74 examining research applications. Educational applications included the use of LLMs for examination preparation, question and case generation, and image‐based learning through generative and adaptive imaging tools. Research applications included machine learning and natural language processing for large‐scale data analysis, pharmacovigilance, social media and clinical text mining, predictive modeling, biomarker and gene‐signature discovery, and the use of LLMs to support literature synthesis, manuscript writing, and research workflow tasks. Across education and research, key limitations related to accuracy, bias, transparency, and ethical governance. These issues highlight the need for ongoing human oversight, the use of dermatology‐specific training datasets, and structured implementation frameworks. Despite these considerations, AI has substantial potential to enhance dermatology learning and improve dermatologic research efficiency. Future work should focus on evaluating real‐world performance, model reliability, and the effectiveness of human‐AI collaboration in dermatology practice and training. image
- 28 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1190-1192
Diagnostic delays and patient experiences in erythropoietic protoporphyria: a multi-site study in Australia
Erythropoietic protoporphyria (EPP) is a rare photodermatosis associated with delayed diagnosis and limited access to specialist care. In this patient-reported survey, we found a median diagnostic delay of 6 years, with many participants expressing unmet needs in follow-up and treatment, and high interest in emerging therapies. These findings highlight the importance of early recognition and improved referral pathways to optimize care for individuals with EPP.
- 28 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1190-1192
Diagnostic delays and patient experiences in erythropoietic protoporphyria: a multi-site study in Australia
Erythropoietic protoporphyria (EPP) is a rare photodermatosis associated with delayed diagnosis and limited access to specialist care. In this patient-reported survey, we found a median diagnostic delay of 6 years, with many participants expressing unmet needs in follow-up and treatment, and high interest in emerging therapies. These findings highlight the importance of early recognition and improved referral pathways to optimize care for individuals with EPP.
- Open Access
- 13 January 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (6) , 1020-1027
An open-label phase II study of bitopertin in adults and adolescents with erythropoietic protoporphyria or X-linked protoporphyria
Background: Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare genetic disorders characterized by accumulation of protoporphyrin IX (PPIX), painful phototoxic reactions and hepatobiliary disease. No disease-modifying therapies are approved for these conditions. Objectives: To evaluate the safety and efficacy of bitopertin in adults and adolescents with EPP or XLP. Methods: BEACON (ACTRN12622000799752) was a phase II, randomized, open-label, parallel-arm study in adult and adolescent participants with EPP or XLP. Participants received an oral, once-daily administration of bitopertin 20 mg or 60 mg for 24 weeks. Results: Twenty-six participants were randomized to 20 mg (n = 14) or 60 mg (n = 12) of bitopertin. The study met its primary efficacy endpoint. Treatment with bitopertin resulted in significant, dose-dependent reductions in PPIX levels compared with baseline at both the 20-mg and 60-mg dose levels (mean −31.7%, SE 7.0; P < 0.001 vs. baseline and mean −57.7%, SE 7.4; P < 0.001 vs. baseline, respectively). Similar efficacy was observed across the adult and adolescent populations. No serious adverse events were reported. Dizziness was the most common adverse event reported with bitopertin, in 9 (64%) and 8 (67%) participants completing the study in the 20-mg and 60-mg dose groups, respectively. Conclusions: By reducing whole-blood PPIX levels, bitopertin targets the underlying pathophysiology of EPP, resulting in consistent improvements in multiple measures of light tolerance and quality of life. Bitopertin was well tolerated, and most adverse events were mild or moderate in severity.
- 13 January 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (6) , 1020-1027
Open AccessAn open-label phase II study of bitopertin in adults and adolescents with erythropoietic protoporphyria or X-linked protoporphyria
Background: Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare genetic disorders characterized by accumulation of protoporphyrin IX (PPIX), painful phototoxic reactions and hepatobiliary disease. No disease-modifying therapies are approved for these conditions. Objectives: To evaluate the safety and efficacy of bitopertin in adults and adolescents with EPP or XLP. Methods: BEACON (ACTRN12622000799752) was a phase II, randomized, open-label, parallel-arm study in adult and adolescent participants with EPP or XLP. Participants received an oral, once-daily administration of bitopertin 20 mg or 60 mg for 24 weeks. Results: Twenty-six participants were randomized to 20 mg (n = 14) or 60 mg (n = 12) of bitopertin. The study met its primary efficacy endpoint. Treatment with bitopertin resulted in significant, dose-dependent reductions in PPIX levels compared with baseline at both the 20-mg and 60-mg dose levels (mean −31.7%, SE 7.0; P < 0.001 vs. baseline and mean −57.7%, SE 7.4; P < 0.001 vs. baseline, respectively). Similar efficacy was observed across the adult and adolescent populations. No serious adverse events were reported. Dizziness was the most common adverse event reported with bitopertin, in 9 (64%) and 8 (67%) participants completing the study in the 20-mg and 60-mg dose groups, respectively. Conclusions: By reducing whole-blood PPIX levels, bitopertin targets the underlying pathophysiology of EPP, resulting in consistent improvements in multiple measures of light tolerance and quality of life. Bitopertin was well tolerated, and most adverse events were mild or moderate in severity.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Dermatological Medicine
- Vol. 2026 (1)
Suspected Penicillamine‐Associated Acquired Cutis Laxa With Ulceration in a Patient With Wilson’s Disease: A Case Report
Penicillamine is a well‐established treatment for Wilson’s disease; however, it is associated with a spectrum of cutaneous complications. It can cause late degenerative skin changes such as acquired cutis laxa. We describe a 77‐year‐old woman with Wilson’s disease, treated with penicillamine for 47 years, who was assessed for painful, nonhealing buttock ulcers present for several years. Penicillamine had been replaced with trientine about 6 months before dermatological review. She was emaciated and had generalized cutis laxa; the ulcers were small and shallow, over the ischial tuberosity and natal cleft. No biopsy was performed as she passed away from pneumonia shortly afterwards. We regard the cutis laxa as suspected penicillamine associated, with age and emaciation as alternative contributors. Recent reports of penicillamine‐associated cutis laxa describe middle‐aged men with histological confirmation. Our patient was instead an elderly, emaciated woman whose presentation was dominated by pressure‐site ulceration and generalized cutis laxa. In such patients, penicillamine may be only one of several contributors to ulceration, alongside age, malnutrition and mechanical stress, so pressure care, nutrition and wound management merit attention alongside review of the drug history. We also highlight common dermatological adverse effects in existing literature, where drug withdrawal may control disease.
- 1 January 2026
- Published by Wiley in Case Reports in Dermatological Medicine
- Vol. 2026 (1)
Open AccessSuspected Penicillamine‐Associated Acquired Cutis Laxa With Ulceration in a Patient With Wilson’s Disease: A Case Report
Penicillamine is a well‐established treatment for Wilson’s disease; however, it is associated with a spectrum of cutaneous complications. It can cause late degenerative skin changes such as acquired cutis laxa. We describe a 77‐year‐old woman with Wilson’s disease, treated with penicillamine for 47 years, who was assessed for painful, nonhealing buttock ulcers present for several years. Penicillamine had been replaced with trientine about 6 months before dermatological review. She was emaciated and had generalized cutis laxa; the ulcers were small and shallow, over the ischial tuberosity and natal cleft. No biopsy was performed as she passed away from pneumonia shortly afterwards. We regard the cutis laxa as suspected penicillamine associated, with age and emaciation as alternative contributors. Recent reports of penicillamine‐associated cutis laxa describe middle‐aged men with histological confirmation. Our patient was instead an elderly, emaciated woman whose presentation was dominated by pressure‐site ulceration and generalized cutis laxa. In such patients, penicillamine may be only one of several contributors to ulceration, alongside age, malnutrition and mechanical stress, so pressure care, nutrition and wound management merit attention alongside review of the drug history. We also highlight common dermatological adverse effects in existing literature, where drug withdrawal may control disease.